insulin glulisine

Insulin glulisine is a rapid-acting recombinant human insulin analog used to improve glycemic control in adults and children with diabetes mellitus. Produced via recombinant DNA technology using a non-pathogenic laboratory strain of Escherichia coli (K12), the molecule differs from human insulin by the substitution of the amino acid asparagine at position B3 with lysine and the replacement of lysine at position B29 with glutamic acid. These structural modifications allow for more rapid absorption and a shorter duration of action compared to regular human insulin, making it suitable for prandial (mealtime) administration. In the context of clinical research at Cairo University, insulin glulisine has been investigated in a Phase 4 trial (NCT01855243) as part of a basal-bolus regimen (in combination with insulin glargine) for the management of hyperglycemia in hospitalized patients with type 2 diabetes mellitus and liver cirrhosis. The study aimed to establish a consensus for inpatient glycemic management in this specific population by comparing the basal-bolus approach against sliding scale regular insulin and NPH plus regular insulin regimens.

Brand names

Apidra

Other names

insulin glulisine3B-Lys-29BGlu-human insulin